Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Journal of Medicinal Chemistry
|
July 12, 2021
Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit
Francesco Rianjongdee, Stephen J Atkinson, Chun-Wa Chung, et al.
Journal of Medicinal Chemistry
|
May 16, 2020
Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains
Michael A Clegg, Paul Bamborough, Chun-Wa Chung, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors
Simon C C Lucas, Stephen J Atkinson, Chun-Wa Chung, et al.
Frontiers in Pharmacology
|
November 19, 2019
Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis
Rosario Luque-Martin, Jan Van den Bossche, Rebecca C Furze, et al.
Journal of Medicinal Chemistry
|
July 22, 2020
Design and Synthesis of a Highly Selective and <i>In Vivo</i>-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins
Alex Preston, Stephen Atkinson, Paul Bamborough, et al.
Cells
|
September 23, 2022
A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease
Ahmed M I Elfiky, Ishtu L Hageman, Marte A J Becker, et al.
Journal of Medicinal Chemistry
|
July 7, 2021
Identification of a Series of <i>N</i>-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins
Lee A Harrison, Stephen J Atkinson, Anna Bassil, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
August 14, 2020
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype
Christopher R Wellaway, Paul Bamborough, Sharon G Bernard, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Journal of Medicinal Chemistry
|
July 12, 2021
Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit
Francesco Rianjongdee, Stephen J Atkinson, Chun-Wa Chung, et al.
Journal of Medicinal Chemistry
|
May 16, 2020
Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains
Michael A Clegg, Paul Bamborough, Chun-Wa Chung, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors
Simon C C Lucas, Stephen J Atkinson, Chun-Wa Chung, et al.
Frontiers in Pharmacology
|
November 19, 2019
Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis
Rosario Luque-Martin, Jan Van den Bossche, Rebecca C Furze, et al.
Journal of Medicinal Chemistry
|
July 22, 2020
Design and Synthesis of a Highly Selective and <i>In Vivo</i>-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins
Alex Preston, Stephen Atkinson, Paul Bamborough, et al.
Cells
|
September 23, 2022
A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease
Ahmed M I Elfiky, Ishtu L Hageman, Marte A J Becker, et al.
Journal of Medicinal Chemistry
|
July 7, 2021
Identification of a Series of <i>N</i>-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins
Lee A Harrison, Stephen J Atkinson, Anna Bassil, et al.
ACS Medicinal Chemistry Letters
|
August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
March 4, 2021
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E Aylott, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
August 14, 2020
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype
Christopher R Wellaway, Paul Bamborough, Sharon G Bernard, et al.
Page
of 5